The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.

Emergent BioSolutions Inc (EBS) reports a robust financial performance with a 9% revenue increase and significant debt reduction, despite challenges in Narcan sales.

November 6, 2024Emergent BioSolutions Inc. beats earnings expectations. Reported EPS is $1.37, expectations were $0.14.

Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

On Thursday, Emergent Biosolutions Inc (EBS) stock saw a modest uptick, ending the day at $11 which represents a slight increase of $1.80 or 19.57% from the prior close of $9.2. The stock opened at ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Emergent BioSolutions Inc. is heading into its next chapter — or “turnaround” phase, as its CEO describes it — after a strong ...

The U.S. overdose crisis and its racial disparities were overlooked in the election, as Black and Indigenous Americans face rising death rates.

Emergent Biosolutions ( (EBS) ) has released its Q3 earnings. Here is a breakdown of the information Emergent Biosolutions presented to its ...

Emergent BioSolutions (EBS) is up 23.7%, or $2.18 to $11.38. Published first on TheFly – the ultimate source for real-time, ...

Thursday after the company reported strong third-quarter results, lifting retail sentiment. Earnings per share for Q3 came in ...

Shares of Emergent Biosolutions climbed after the company reported an increase in revenue and swung to a profit in the third quarter. The stock was up 28% to $11.81 in Thursday afternoon trading.